BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

976 related articles for article (PubMed ID: 26791235)

  • 21. miR-101 suppresses the development of
    Gonzales-Aloy E; Connerty P; Salik B; Liu B; Woo AJ; Haber M; Norris MD; Wang J; Wang JY
    Haematologica; 2019 Jul; 104(7):e296-e299. PubMed ID: 30792205
    [No Abstract]   [Full Text] [Related]  

  • 22. An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in
    Wang H; Shah CA; Hu L; Huang W; Platanias LC; Eklund EA
    J Biol Chem; 2020 Jul; 295(28):9663-9675. PubMed ID: 32467231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development.
    Schneider E; Staffas A; Röhner L; Krowiorz K; Heuser M; Döhner K; Bullinger L; Döhner H; Fogelstrand L; Rouhi A; Kuchenbauer F; Palmqvist L
    Exp Hematol; 2016 Dec; 44(12):1166-1171. PubMed ID: 27619068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
    Wang Y; Skibbe JR; Hu C; Dong L; Ferchen K; Su R; Li C; Huang H; Weng H; Huang H; Qin X; Jin J; Chen J; Jiang X
    Sci Rep; 2017 May; 7(1):1853. PubMed ID: 28500307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
    Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
    Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TRIB2 regulates the differentiation of MLL-TET1 transduced myeloid progenitor cells.
    Kim HS; Oh SH; Kim JH; Sohn WJ; Kim JY; Kim DH; Choi SU; Park KM; Ryoo ZY; Park TS; Lee S
    J Mol Med (Berl); 2018 Nov; 96(11):1267-1277. PubMed ID: 30324339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia.
    Verboon LJ; Obulkasim A; de Rooij JD; Katsman-Kuipers JE; Sonneveld E; Baruchel A; Trka J; Reinhardt D; Pieters R; Cloos J; Kaspers GJ; Klusmann JH; Zwaan CM; Fornerod M; van den Heuvel-Eibrink MM
    Oncotarget; 2016 Jul; 7(30):48412-48422. PubMed ID: 27351222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
    Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
    Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia.
    Chen Y; Anastassiadis K; Kranz A; Stewart AF; Arndt K; Waskow C; Yokoyama A; Jones K; Neff T; Lee Y; Ernst P
    Cancer Cell; 2017 Jun; 31(6):755-770.e6. PubMed ID: 28609655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
    Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
    Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initiation of MLL-rearranged AML is dependent on C/EBPα.
    Ohlsson E; Hasemann MS; Willer A; Lauridsen FK; Rapin N; Jendholm J; Porse BT
    J Exp Med; 2014 Jan; 211(1):5-13. PubMed ID: 24367003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
    Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
    J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular pathogenesis of disease progression in MLL-rearranged AML.
    Kotani S; Yoda A; Kon A; Kataoka K; Ochi Y; Shiozawa Y; Hirsch C; Takeda J; Ueno H; Yoshizato T; Yoshida K; Nakagawa MM; Nannya Y; Kakiuchi N; Yamauchi T; Aoki K; Shiraishi Y; Miyano S; Maeda T; Maciejewski JP; Takaori-Kondo A; Ogawa S; Makishima H
    Leukemia; 2019 Mar; 33(3):612-624. PubMed ID: 30209403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.
    Li Z; Huang H; Chen P; He M; Li Y; Arnovitz S; Jiang X; He C; Hyjek E; Zhang J; Zhang Z; Elkahloun A; Cao D; Shen C; Wunderlich M; Wang Y; Neilly MB; Jin J; Wei M; Lu J; Valk PJM; Delwel R; Lowenberg B; Le Beau MM; Vardiman J; Mulloy JC; Zeleznik-Le NJ; Liu PP; Zhang J; Chen J
    Nat Commun; 2012 Feb; 3():688. PubMed ID: 22353710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SON and Its Alternatively Spliced Isoforms Control MLL Complex-Mediated H3K4me3 and Transcription of Leukemia-Associated Genes.
    Kim JH; Baddoo MC; Park EY; Stone JK; Park H; Butler TW; Huang G; Yan X; Pauli-Behn F; Myers RM; Tan M; Flemington EK; Lim ST; Ahn EY
    Mol Cell; 2016 Mar; 61(6):859-73. PubMed ID: 26990989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Menin critically links MLL proteins with LEDGF on cancer-associated target genes.
    Yokoyama A; Cleary ML
    Cancer Cell; 2008 Jul; 14(1):36-46. PubMed ID: 18598942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent
    Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
    Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis.
    Bagislar S; Sabò A; Kress TR; Doni M; Nicoli P; Campaner S; Amati B
    Oncotarget; 2016 Oct; 7(41):66398-66415. PubMed ID: 27655694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.